KMT2D and cancer: These approaches allowed us to detect higher frequencies of somatic mutations in key cancer genes, including TP53 (11%), SYNE1 (11%), EP400 (9%), CSMD3 (9%), NFKBIA (9%), and KMT2D (9%).